Actinium Pharmaceuticals Inc
Research Actinium Pharmaceuticals Inc (ATNM) on Bullrun: market cap USD 34.59M, P/E 3.1. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerATNM
- ExchangeNYSE MKT
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 34.59M
- P/E3.1
- Financial periodQ2 2026
- RevenueUSD 35.00M
- Net incomeUSD 27.90M
- Free cash flow-USD 5.66M
Valuation Snapshot
latest market cap is USD 34.59M; P/E is 3.1.
Peer valuation comparison
Latest P/E is 3.08x versus a Healthcare sector median of 24.61x (87.5% below).
Latest P/E is 3.08x versus a United States median of 23.85x (87.1% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 90.00K | -USD 33.89M | -USD 24.68M | n/a | -1.09 | USD 48.00M | USD 1.69M | USD 7.83M |
| FY2024 | USD 0 | -USD 38.24M | -USD 33.08M | n/a | -1.27 | USD 72.90M | USD 1.57M | USD 32.76M |
| FY2023 | USD 81.00K | -USD 48.82M | -USD 47.49M | n/a | -1.83 | USD 76.68M | USD 2.11M | USD 36.38M |
| FY2022 | USD 1.03M | -USD 33.02M | USD 8.28M | n/a | -1.37 | USD 108.91M | USD 2.58M | USD 66.48M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 34.59M | 3.1 | n/a | n/a |
| 2025 | 2025-12-31 | USD 42.43M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 39.31M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 139.26M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 271.40M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 133.09M | n/a | n/a | n/a |
About Actinium Pharmaceuticals Inc
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T and gene therapies for non-malignant hematologic disorders such as sickle cell disease.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Actinium Pharmaceuticals Inc's market cap?
Actinium Pharmaceuticals Inc's market capitalization is USD 34.59M.
What is Actinium Pharmaceuticals Inc's P/E ratio?
Actinium Pharmaceuticals Inc's price-to-earnings (P/E) ratio is 3.1.
What does Actinium Pharmaceuticals Inc do?
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T and gene therapies for non-malignant hematologic disorders such as sickle cell disease.